Nov 08, 2023 / 01:00PM GMT
Trung Chuong Huynh - UBS Investment Bank, Research Division - Analyst
Okay. It's 8:00 a.m. My name is Trung Huynh. I'm one of the therapeutics analyst here at UBS. It's my great pleasure to present to you guys Bristol-Myers Squibb, our first fireside session, our conference.
Today, we're talking about cell therapy for the next 45 minutes. We've got Lynelle Hoch, who is the Head of Cell Therapy at BMY, and we've also got IR here in the room. Welcome.
Lynelle Hoch - Bristol-Myers Squibb Company - President of Cell Therapy Organization
Thank you. Great to be here.
Questions and Answers:
Trung Chuong Huynh - UBS Investment Bank, Research Division - AnalystYou guys are one of the pioneers of cell therapy. When I first looked at cell therapy, I thought to myself, my God, this is not going to work. And there were many challenges. Challenges around manufacturing, challenges around vector, supply, reimbursements, you guys have made significant progress over the last 5 years to try to address all of these